Deutsche Bank Downgrades Novartis to Sell Following Mixed Q3 Results
Deutsche Bank has downgraded Swiss pharmaceutical giant Novartis (NVS) from Hold to Sell. The decision follows a recent review of the company's third-quarter performance, which analysts characterized as mixed. Analyst Emmanuel Papadakis cited concerns regarding the company's trajectory following its latest financial disclosures. This downgrade suggests a shift in market sentiment toward a more cautious outlook for the drugmaker's near-term growth prospects.
